Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy.
A ppt about hemophilia, Including a good video. This is about what is hemophilia, why is it there, is it a genetic disorder? What percentage of people get it? Whats the average lifespan now and then?
Hemophilia is a bleeding disorder that slows down the blood clotting process. People who have hemophilia often have longer bleeding after an injury or surgery. People who have severe hemophilia have spontaneous bleeding into the joints and muscles. Hemophilia occurs more commonly in males than in females.The two most common types of hemophilia are hemophilia A (also known as classic hemophilia) and hemophilia B (also known as Christmas disease). People who have hemophilia A have low levels of a blood clotting factor called factor eight (FVIII). People who have hemophilia B have low levels of factor nine (FIX).
The two types of hemophilia are caused by permanent gene changes (mutations) in different genes. Mutations in the FVIII gene cause hemophilia A. Mutations in the FIX gene cause hemophilia B. Proteins made by these genes have an important role in the blood clotting process. Mutations in either gene keep clots from forming when there is an injury, causing too much bleeding that can be difficult to stop
Hemophilia A is the most common type of this condition. One in 5,000 to 10,000 males worldwide have hemophilia A. Hemophilia B is less common, and it affects 1 in 20,000 to 34,500 males worldwide.
A ppt about hemophilia, Including a good video. This is about what is hemophilia, why is it there, is it a genetic disorder? What percentage of people get it? Whats the average lifespan now and then?
Hemophilia is a bleeding disorder that slows down the blood clotting process. People who have hemophilia often have longer bleeding after an injury or surgery. People who have severe hemophilia have spontaneous bleeding into the joints and muscles. Hemophilia occurs more commonly in males than in females.The two most common types of hemophilia are hemophilia A (also known as classic hemophilia) and hemophilia B (also known as Christmas disease). People who have hemophilia A have low levels of a blood clotting factor called factor eight (FVIII). People who have hemophilia B have low levels of factor nine (FIX).
The two types of hemophilia are caused by permanent gene changes (mutations) in different genes. Mutations in the FVIII gene cause hemophilia A. Mutations in the FIX gene cause hemophilia B. Proteins made by these genes have an important role in the blood clotting process. Mutations in either gene keep clots from forming when there is an injury, causing too much bleeding that can be difficult to stop
Hemophilia A is the most common type of this condition. One in 5,000 to 10,000 males worldwide have hemophilia A. Hemophilia B is less common, and it affects 1 in 20,000 to 34,500 males worldwide.
Hemophilia is a genetic bleeding disorder in which body loses the ability to stop bleeding due to low levels or absence of proteins known as ‘’clotting factors’’ which are necessary for clotting of blood. Hemophilia leads to excessive bleeding.
Hemophilia is a common hereditary coagulation disorder due to deficiency or reduce activity of clotting factor VIII or clotting factor IX.
This disorder is a X- linked recessive disorder.
Types:
Hemophilia A- deficiency of clotting factors VIII
Hemophilia B- deficiency of clotting factors IX
Hemophilia C- deficiency of clotting factors XI
Parahaemophilia- deficiency of clotting factor V
Causes of hemophilia
Hemophilia has a sex-linked recessive inheritance.
In most cases Hemophilia caused by a mutation in a gene that encodes for one of the clotting factors .
Since the hemophilia gene is located on the X chromosome, Hemophilia usually occurs in males, and Female is the carrier of hemophilia.
Diagnosis
Complete blood cell count
Coagulation studies
FVIII assay
Normal values for FVIII assays are 50-150%. Values in hemophilia are as follows:
Mild: >5%
Moderate: 1-5%
Severe: <1%
Treatment of Hemophilia
Other Types of Treatment
Desmopressin (DDAVP)
Antifibrinolytic Medicines
Vaccinations- hepatitis A and B.
Gene Therapy
Gene Therapy
New Drugs for Hemophilia treatment
New Drugs for Hemophilia treatment
Bangladesh perspectives
Bangladesh would have 10800 hemophiliacs.
But, initially the patients does not concern about hemophilia.
Patients are usually diagnosed only after bleeding episode and sometimes the episode are causes serious consequences.
Conclusion
Primary diagnosis with the success of gene therapy and availability of the new bioengineered products the prospect of the hemophiliacs will be brighter in near future.
Hemophilia is a genetic bleeding disorder in which body loses the ability to stop bleeding due to low levels or absence of proteins known as ‘’clotting factors’’ which are necessary for clotting of blood. Hemophilia leads to excessive bleeding.
Hemophilia is a common hereditary coagulation disorder due to deficiency or reduce activity of clotting factor VIII or clotting factor IX.
This disorder is a X- linked recessive disorder.
Types:
Hemophilia A- deficiency of clotting factors VIII
Hemophilia B- deficiency of clotting factors IX
Hemophilia C- deficiency of clotting factors XI
Parahaemophilia- deficiency of clotting factor V
Causes of hemophilia
Hemophilia has a sex-linked recessive inheritance.
In most cases Hemophilia caused by a mutation in a gene that encodes for one of the clotting factors .
Since the hemophilia gene is located on the X chromosome, Hemophilia usually occurs in males, and Female is the carrier of hemophilia.
Diagnosis
Complete blood cell count
Coagulation studies
FVIII assay
Normal values for FVIII assays are 50-150%. Values in hemophilia are as follows:
Mild: >5%
Moderate: 1-5%
Severe: <1%
Treatment of Hemophilia
Other Types of Treatment
Desmopressin (DDAVP)
Antifibrinolytic Medicines
Vaccinations- hepatitis A and B.
Gene Therapy
Gene Therapy
New Drugs for Hemophilia treatment
New Drugs for Hemophilia treatment
Bangladesh perspectives
Bangladesh would have 10800 hemophiliacs.
But, initially the patients does not concern about hemophilia.
Patients are usually diagnosed only after bleeding episode and sometimes the episode are causes serious consequences.
Conclusion
Primary diagnosis with the success of gene therapy and availability of the new bioengineered products the prospect of the hemophiliacs will be brighter in near future.
Global Apheresis Market Analysis Sample ReportInsights10
The Global apheresis market is projected to grow from $3.6 Mn in 2022 to $6.4 Mn in 2030 with a CAGR of 8% for the year 2022-2030. Growth of the market will be mainly driven by the rising prevalence of chronic diseases and a growing number of trauma and injury cases. Fresenius Kabi and Terumo are key players in the market. To get a detailed report, contact us at - info@insights10.com
Hepatitis is the inflammation of the liver. The condition can be limited to self or can advance to scarring, cirrhosis or liver cancer. Hepatitis viruses are the most common origin of Hepatitis in all over the world. Sometimes, other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can also cause Hepatitis.
Apheresis involves removing whole blood from a donor or
patient by passing it through a medical device and
separating the blood into individual components so that
one particular component can be removed
The remaining blood components then are re introduced
back into the bloodstream of the patient or donor
Used for collection of donor blood components and for
the treatment for certain medical conditions
Process takes two to four hours and is similar to a regular
blood donation
Involves laboratory medicine, clinical hematology
laboratory, pediatric hematology and oncology
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Incidence of haemophilia, genealogical inheritance and transmission of haemop...IJMREMJournal
Introduction: Haemophilia is a state of bleeding. In the blood there is a lack of coagulation factor that controls
blood flow.
GOAL: to show the number and treatment of cases of haemophilia, their treatment, and display a family tree.
MATERIALS AND METHODS: a descriptive and epidemiological method of data capture and are
presented in a tabular and graphical way.
RESULTS AND DISCUSSION: Familial positive history in 53 individuals or 91.38% has not been done
prenatal diagnosis, or only in 3,45% a prenatal diagnosis has been made. Bloody symptoms have 55 or 94.83%,
with 40 or 68.9% of them having spontaneous bleeding episodes. Out of 40 people or 68.97% are on permanent
treatment. Of these, indicative treatment is 32 persons or 55.17%, prophylaxis is 9 persons or 15.52%, 11
persons change the treatment or 18.97% and 6 people are unfamiliar or 10.34% are treated. Of the examinees,
39 people or 67.24% receive a coagulation factor, and 19 people or 32.76% do not receive a coagulation
factor.
CONCLUSION: the available therapeutic possibilities are concentrated on an indicator factor and a small
percentage of prophylactic treatment, an institutional therapy, but there are also therapeutic agents that are not
available for people with coagulopathies.
Medical second opinion market Size, Share, Growth Business Strategy and Forec...jitendra more
Increasing number of errors in medical billing is also one of the prominent factors responsible for the growth of the market. For instance,according to a study published by the Medical Billing Advocates of America in2019, an estimated 80.0% of medical bills contain at least one error. Further,problems in medical billing errors cost a total of ~US$ 210 billion each year in the US. These possibilities and occurrences of financial errors areprojected to accelerate the growth of the medical second opinion market by 2027.
Pain Management Devices Market: Increasing Chronic Pain Incidencesjitendra more
These diseases affect a person's health critically by lowering immunity and resulting in chronic pain. The incidences of the aforementioned diseases are most commonly seen in adults and geriatric population.
Smart water meter: Rise in water scarcity crisis coupled with the exploitatio...jitendra more
The world is facing a huge scarcity of water owing to practices such as illegal tapping, tampering of pipelines, and leakage among others. Owing to this, water scarcity is rapidly increasing in the current scenario and the issue is anticipated to increase in the near future. According to WWF (World Wildlife Fund), approximately 1.1 Bn people globally lack access to water, totaling to 2.7 Bn find water scarce. In addition to this, another major problem faced by various regions is the misuse of water which has significantly raised the demand for advanced solutions to maintain the consumption pattern from the source to destination.
Read more @ https://www.theinsightpartners.com/reports/smart-water-meters-market
AI (Artificial Intelligence) Chip Market Growing Technology Trends and Busine...jitendra more
The global artificial intelligence chip market was valued at US$ 5,658.1 Mn in 2018 and is expected to reach US$ 83,252.7 Mn by 2027 with a CAGR growth rate of 35.0% in the forecast period from 2019 to 2027.
Air Cargo Market Analysis Share, Growth, Trends and Future Prospectsjitendra more
The global air cargo market valued at US$ 102.00 Bn in 2018 and is expected to grow at a CAGR of 4.1% during the forecast period 2019 – 2027, to account to US$ 145.20 Bn by 2027.
Rising e-commerce industry as well as relocation of manufacturing in ASEAN countries propelling the air cargo market in the APAC region. The key players operating in the air cargo market includes FedEx Express, UPS Airlines, DHL Aviation, Emirates, Cathay Pacific Airways, Korean Air Cargo, Lufthansa, Singapore Airlines Cargo, China Airlines, British Airways, Cargolux, ANA CARGO, and Zela Aviation The Air Charter Company among others.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Hemophilia Treatment Market Analysis, Trends and Future Prospects
1. Hemophilia Treatment Market
Hemophilia Treatment Market to 2027 -
Global Analysis and Forecasts by Product
(Plasma Derived Coagulation Factor
Concentrates, Recombinant Coagulation
Factor Concentrates, Desmopressin,
Antifibrinolytic Agents); Disease
(Hemophilia A, Hemophilia B, Hemophilia
C); Treatment Type (On-demand,
Prophylaxis); Therapy (Replacement
Therapy, ITI Therapy, Gene Therapy,
Antibody Therapy); End User (Hospitals,
Clinics, Ambulatory Surgical Centres,
Others), and Geography
2. Current and future Market Scenario
According to a new market research study titled ‘Hemophilia Treatment Market - Global Analysis and Forecasts by
Product, Disease, Treatment Type, Therapy, and End User, the global hemophilia treatment market is expected to reach
US$ 44,089.71 Mn in 2027 from US$ 14,454.81 Mn in 2019.
The market is estimated to grow with a CAGR of 15.9% from 2020-2027. The report highlights the trends prevalent in the
global hemophilia treatment market and the factors driving the market along with those that act as deterrents to its
growth.
The hemophilia treatment market by product is segmented into plasma derived coagulation factor concentrates,
recombinant coagulation factor concentrates, antifibrinolytic agents, desmopressin. In 2019, the plasma derived
coagulation factor concentrates segment held a largest market share of the hemophilia treatment market.
This segment is also expected to dominate the market in 2027. The large share of plasma derived coagulation factor
concentrates based hemophilia treatment can be attributed to various advantages offered by these hemophilia
treatment, deep market penetration and variety of products offered by multiple players to suit diverse medical
application.
Hemophilia Treatment Market
3. Key Findings
On the other hand, the recombinant coagulation factor concentrates segment is anticipated to witness the highest
growth rate during the forecast period. Certain factors such as effectiveness of the hemophilia treatment in lesser time
and better efficient blood clotting are expected to drive the segment growth.
Factors such as increase in the number of surgical procedures and an increasing incidences of sports injuries are
expected to upsurge the market growth. In addition, growth in the global healthcare market is likely to have a positive
impact on the growth of the market in the coming years.
Market Insights
Increasing Prevalence of Hemophilia
Hemophilia is a hereditary bleeding disorder that stops the blood from clotting normally. The primary symptom is
uncontrolled, often spontaneous bleeding in different areas of the body. According to data from the National Hemophilia
Foundation in 2020, Hemophilia A happens in 1 in 5,000 live male births. Hemophilia A is about four times as common as
hemophilia B. The number of people with hemophilia in the United States is anticipated to be around 20,000 individuals.
Moreover, the incidence of hemophilia is not known across the globe but projected at above 400,000 people. Almost 75%
of people with hemophilia worldwide are either undiagnosed or receive disparate treatment.
4. Market Segments
Hemophilia Treatment Market
By Product (Plasma Derived
Coagulation Factor Concentrates,
Recombinant Coagulation Factor
Concentrates, Desmopressin,
Antifibrinolytic Agents)
Disease
(Hemophilia A, Hemophilia B,
Hemophilia C)
Treatment Type (On-demand,
Prophylaxis); Therapy
(Replacement Therapy, ITI Therapy,
Gene Therapy, Antibody Therapy)
5. Dominating Segments
Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition
is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are
widely seen in males as the X chromosome is inherited from mother to baby boy.
The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used
is medication. However, there are ways to reduce the risk of the condition, which include regular exercise
and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII
for hemophilia A, or IX for hemophilia B.
In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the
number of registered people with bleeding disorders increased from about 7000 in 2000 to around 8500 in
2011 and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are
recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.
Hemophilia Treatment Market
6. Product Insights
Products Insights
The plasma derived coagulation factor concentrates based hemophilia treatment captured the largest share in the
global hemophilia treatment market. A wide variety of hemophilia treatment is available as adjunctive measures
to improve hemophilia if residual bleeding persists despite the correct application of conventional methods for
hemorrhage control.
Plasma-derived coagulation factor hemophilia treatment is considered to be active agents that participate in the
coagulation cascade to form fibrin clots and are effective to make an intact coagulation system. Plasma is the
liquid part of blood. It is pale yellow or straw-colored with proteins such as antibodies, albumin, and coagulation
factors. There are several target factor drug products made from plasma proteins of human. The plasma is
collected from group of people, and perform several processes to separate the plasma into its components.
Download PDF Brochure https://www.theinsightpartners.com/sample/TIPRE00008241/
Dominating Segments
7. The report segments the global hemophilia treatment market as follows:
Global Hemophilia Treatment Market – By Product
Plasma Derived Coagulation Factor Concentrates
Factor VIII Market
Factor IX Market
Factor XIII Market
Activated Prothrombin Complex Concentrate Market
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytic Agents
Global Hemophilia Treatment Market – By Disease
Hemophilia A
Hemophilia B
Dominating Segments
8. Global Hemophilia Treatment Market – By Treatment Type
On demand
Prophylaxis
Global Hemophilia Treatment Market – By Therapy
Replacement Therapy
ITI Therapy
Gene Therapy
Antibody Therapy
Global Hemophilia Treatment Market – By End User
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Dominating Segments
9. Leading Players
Hemophilia Treatment Market
Company Profiles in Hemophilia Treatment Market are:
Bayer AG
Sanofi
F. Hoffmann-la Roche Ltd.
Kedrion S.P.A.
CSL Limited
Biotest AG
Pfizer Inc.
Novo Nordisk A/S
Octapharma AG
Baxter International Inc.
